Recent clinical experience with vaccines using MPL- and QS-21-containing Adjuvant Systems

Expert Review of Vaccines

Volumn 10, Issue 4, 2011, Pages 471-486

  Garçon, Nathalie ^a   Van Mechelen, Marcelle ^a  

^a GLAXOSMITHKLINE BIOLOGICALS   (Belgium)

Author keywords

Adjuvant Systems; AS01; AS02; AS04; immunostimulant; MPL; QS 21; vaccine

Indexed keywords

3 O DESACYL 4' MONOPHOSPHORYL LIPID A; AS01; AS02; AS04; BCG VACCINE; CANCER VACCINE; HEPATITIS B VACCINE; HERPES SIMPLEX VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MELANOMA VACCINE; QS 21; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG MECHANISM; DRUG SAFETY; GENITAL HERPES; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; INNATE IMMUNITY; LUNG NON SMALL CELL CANCER; MALARIA; MELANOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUBERCULOSIS; UTERINE CERVIX CANCER;

ADJUVANTS, IMMUNOLOGIC; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; IMMUNE SYSTEM; IMMUNITY, INNATE; LIPID A; SAPONINS; VACCINES;

EID: 79955086319     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.29     Document Type: Review

References (184)

1. Garccadilon N, Chomez P, Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 6(5), 723-739 (2007). (Pubitemid 47607848)
2. Burdin N, Guy B, Moingeon P. Immunological foundations to the quest for new vaccine adjuvants. BioDrugs 18(2), 79-93 (2004). (Pubitemid 38507891)
3. Guy B. The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol. 5(7), 505-517 (2007). (Pubitemid 46925379)
4. Black M, Trent A, Tirrell M, Olive C. Advances in the design and delivery of peptide subunit vaccines with a focus on Toll-like receptor agonists. Expert Rev. Vaccines 9(2), 157-173 (2010).
5. Gordon DM, McGovern TW, Krzych U et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 171(6), 1576-1585 (1995).
6. Hoffman SL, Edelman R, Bryan JP et al. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am. J. Trop. Med. Hyg. 51(5), 603-612 (1994). (Pubitemid 24378556)
7. Livingston PO, Adluri S, Helling F et al. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine 12(14), 1275-1280 (1994).
8. Rickman LS, Wistar R, Hoffman SL et al. Use of adjuvant containing mycobacterial cell-wall skeleton, monophosphoryl lipid A, and squalane in malaria circumsporozoite protein vaccine. Lancet 337(8748), 998-1001 (1991).
9. van Dissel JT, Arend SM, Prins C et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 28(20), 3571-3581 (2010).
10. Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336(2), 86-91 (1997). (Pubitemid 27020884)
11. André FE. Clinical experience with a recombinant DNA hepatitis B vaccine. Southeast Asian J. Trop. Med. Public Health 19(3), 501-510 (1988).
12. Vogel FR. Adjuvants in perspective. Dev. Biol. Stand. 92, 241-248 (1998).
13. Casella CR, Mitchell TC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci. 65(20), 3231-3240 (2008).
14. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work. Immunity 33(4), 492-503 (2010).
15. Brunner R, Jensen-Jarolim E, Pali-Schöll I. The ABC of clinical and experimental adjuvants-a brief overview. Immunol. Lett. 128(1), 29-35 (2010).
16. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 272(5258), 50-53 (1996).
17. Poltorak A, He X, Smirnova I et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in tlr4 gene. Science 282(5396), 2085-2088 (1998). (Pubitemid 29001265)
18. Beutler B, Rietschel ET. Innate immune sensing and its roots: the story of endotoxin. Nat. Rev. Immunol. 3(2), 169-176 (2003). (Pubitemid 37328694)
19. Hofmann MA, Drury S, Fu C et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/ calgranulin polypeptides. Cell 97(7), 889-901 (1999). (Pubitemid 29375048)
20. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 425(6957), 516-521 (2003). (Pubitemid 37237047)
21. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell 91(3), 295-298 (1997). (Pubitemid 27467959)
22. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388(6640), 394-397 (1997). (Pubitemid 27334820)
23. Qureshi N, Mascagni P, Ribi E, Takayama K. Monophosphoryl lipid A obtained from lipopolysaccharides of Salmonella minnesota R595. Purification of the dimethyl derivative by high performance liquid chromatography and complete structural determination. J. Biol. Chem. 260(9), 5271-5278 (1985). (Pubitemid 15003265)
24. Baldridge JR, Myers K, Johnson D, Persing D, Cluff C, Hershberg R. Monophosphoryl lipid A and synthetic lipid A mimetics as TLR4-based adjuvants and immunomodulators. In:Vaccine Adjuvants: Immunological and Clinical Principles. Hackett CJ, Harn DA Jr (Eds).Humana Press Inc., Totowa, NJ, USA, 235-255 (2008).
25. Kensil CR, Patel U, Lennick M, Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. J. Immunol. 146(2), 431-437 (1991).
26. Kensil CR, Kammer R. QS-21: a water-soluble triterpene glycoside adjuvant. Expert Opin. Investig. Drugs. 7(9), 1475-1482 (1998). (Pubitemid 28408808)
27. Newman MJ, Wu JY, Gardner BH et al. Saponin adjuvant induction of ovalbumin-specific CD8+ cytotoxic T lymphocyte responses. J. Immunol. 148(8), 2357-2362 (1992).
28. Garccadilon N, Heppner DG, Cohen J. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev. Vaccines 2(2), 231-238 (2003). (Pubitemid 36559928)
29. Didierlaurent AM, Morel S, Lockman L et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183(10), 6186-6197 (2009).
30. Giannini SL, Hanon E, Moris P et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 24(33-34), 5937-5949 (2006). (Pubitemid 44080367)
31. Boring L, Gosling J, Chensue SW et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J. Clin. Invest. 100(10), 2552-2561 (1997). (Pubitemid 27514895)
32. Serbina NV, Jia T, Hohl TM, Pamer EG. Monocyte-mediated defense against microbial pathogens. Annu. Rev. Immunol. 26, 421-452 (2008). (Pubitemid 351600381)
33. Brewer JM. (How) do aluminium adjuvants work? Immunol. Lett. 102(1), 10-15 (2006).
34. Eddahri F, Denanglaire S, Bureau F et al. Interleukin-6/STAT3 signaling regulates the ability of naive T cells to acquire B-cell help capacities. Blood 113(11), 2426-2433 (2009).
35. Marciani DJ. Vaccine adjuvants: role and mechanisms of action in vaccine immunogenicity. Drug Discov. Today 8(20), 934-943 (2003). (Pubitemid 37230013)
36. Soltysik S, Wu JY, Recchia J et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 13(15), 1403-1410 (1995).
37. Marciani DJ, Pathak AK, Reynolds RC, Seitz L, May RD. Altered immunomodulating and toxicological properties of degraded Quillaja saponaria Molina saponins. Int. Immunopharmacol. 1(4), 813-818 (2001). (Pubitemid 32206543)
38. Liu G, Anderson C, Scaltreto H, Barbon J, Kensil CR. QS-21 structure/function studies: effect of acylation on adjuvant activity. Vaccine 20(21-22), 2808-2815 (2002). (Pubitemid 34597141)
39. Rhodes J, Chen H, Hall SR et al. Therapeutic potentiation of the immune system by costimulatory Schiff-base-forming drugs. Nature 377(6544), 71-75 (1995).
40. Mettens P, Dubois PM, Demoitié MA et al. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. Vaccine 26(8), 1072-1082 (2008).
41. Pichyangkul S, Kum-Arb U, Yongvanitchit K et al. Preclinical evaluation of the safety and immunogenicity of a vaccine consisting of Plasmodium falciparum liver-stage antigen 1 with adjuvant AS01B administered alone or concurrently with the RTS,S/AS01B vaccine in rhesus primates. Infect. Immun. 76(1), 229-238 (2008).
42. Sun P, Schwenk R, White K et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-g. J. Immunol. 171(12), 6961-6967 (2003). (Pubitemid 37532133)
43. Pichyangkul S, Tongtawe P, Kum-Arb U et al. Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system AS02A administered alone or concurrently in rhesus monkeys. Vaccine 28(2), 452-462 (2009).
44. Sallusto F, Lanzavecchia A, Araki K, Ahmed R. From vaccines to memory and back. Immunity 33(4), 451-463 (2010).
45. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47(3), 401-409 (2008).
46. Wrammert J, Smith K, Miller J et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453(7195), 667-671 (2008). (Pubitemid 351769295)
47. Lanzavecchia A, Sallusto F. Human B cell memory. Curr. Opin. Immunol. 21(3), 298-304 (2009).
48. Hofer T, Muehlinghaus G, Moser K et al. Adaptation of humoral memory. Immunol. Rev. 211, 295-302 (2006). (Pubitemid 43882980)
49. Tokoyoda K, Hauser AE, Nakayama T, Radbruch A. Organization of immunological memory by bone marrow stroma. Nat. Rev. Immunol. 10(3), 193-200 (2010).
50. Radbruch A, Muehlinghaus G, Luger EO et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6(10), 741-750 (2006). (Pubitemid 44453460)
51. Kalia V, Sarkar S, Gourley TS, Rouse BT, Ahmed R. Differentiation of memory B and T cells. Curr. Opin. Immunol. 18(3), 255-264 (2006).
52. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu. Rev. Immunol. 22, 745-763 (2004). (Pubitemid 38680440)
53. Masopust D, Vezys V, Marzo AL, Lefrancois L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291(5512), 2413-2417 (2001). (Pubitemid 32231804)
54. Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J. Immunol. Methods 65(1-2), 109-121 (1983). (Pubitemid 14203438)
55. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J. Clin. Pathol. 55(4), 244-265 (2002). (Pubitemid 34293391)
56. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J. Natl Cancer Inst. 92(9), 690-698 (2000). (Pubitemid 30365529)
57. zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology 384(2), 260-265 (2009).
58. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br. J. Cancer 89(1), 101-105 (2003). (Pubitemid 36897943)
59. Walboomers JM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189(1), 12-19 (1999). (Pubitemid 29406813)
60. Muñoz N, Bosch FX, de Sanjosé S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348(6), 518-527 (2003). (Pubitemid 36159887)
61. Bosch FX, de Sanjosé S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J. Natl Cancer Inst. Monogr. (31), 3-13 (2003).
62. Brown DR, Shew ML, Qadadri B et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J. Infect. Dis. 191(2), 182-192 (2005). (Pubitemid 40096375)
63. Koutsky L. Epidemiology of genital human papillomavirus infection. Am. J. Med. 102(5A), 3-8 (1997). (Pubitemid 127695953)
64. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J. Clin. Virol. 32(Suppl. 1), S16-S24 (2005). (Pubitemid 40332585)
65. Schwarz TF, Leo O. Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature. Gynecol. Oncol. 110(3 Suppl. 1), S1-S10 (2008).
66. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 370(9590), 890-907 (2007). (Pubitemid 47371147)
67. Deschuyteneer M, Elouahabi A, Plainchamp D et al. Molecular and structural characterization of the L1 virus-like particles that are used as vaccine antigens in Cervarix™, the AS04-adjuvanted HPV-16 and -18 cervical cancer vaccine. Hum. Vaccin. 6(5), 407-419 (2010).
68. Garccadilon N, Van Mechelen M, Wettendorff M. Development and evaluation of AS04, a novel and improved immunological adjuvant system containing MPL and aluminium salt. In: Immunopotentiators in Modern Vaccines. Elsevier Academic Press, London, UK, 161-178 (2006).
69. Kemp TJ, García-Piñeres A, Falk RT et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 26(29-30), 3608-3616 (2008).
70. Schwarz TF, Kocken M, Petäjä T et al. Correlation between levels of human papillomavirus (HPV)-16 and 18 antibodies in serum and cervicovaginal secretions in girls and women vaccinated with the HPV-16/18 AS04-adjuvanted vaccine. Hum. Vaccin. 6(12), 1054-1061 (2010).
71. Schwarz TF, Spaczynski M, Schneider A et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 27(4), 581-587 (2009).
72. Einstein MH, Baron M, Levin MJ et al. Comparison of the immunogenicity and safety of Cervarix™ and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum. Vaccin. 5(10), 705-719 (2009).
73. Harper DM, Franco EL, Wheeler C et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364(9447), 1757-1765 (2004). (Pubitemid 39488060)
74. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367(9518), 1247-1255 (2006).
75. Schwarz TF. AS04-adjuvanted human papillomavirus-16/18 vaccination: recent advances in cervical cancer prevention. Expert Rev. Vaccines 7(10), 1465-1473 (2008).
76. Romanowski B, de Borba PC, Naud PS et al. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 374(9706), 1975-1985 (2009).
77. Paavonen J, Naud P, Salmerón J et al. Efficacy of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 374(9686), 301-314 (2009).
78. de Carvalho N, Teixeira J, Roteli- Martins CM et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 28(38), 6247-6255 (2010).
79. Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus type 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: final analysis of a Phase 2 double-blind, randomized controlled trial. Int. J. Gynecol. Cancer 20(5), 847-855 (2010).
80. Konno R, Tamura S, Dobbelaere K, Yoshikawa H. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a Phase 2 double-blind, randomized, controlled trial. Int. J. Gynecol. Cancer 20(3), 404-410 (2010).
81. Bhatla N, Suri V, Basu P et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine in healthy Indian women. J. Obstet. Gynaecol. Res. 36(1), 123-132 (2010).
82. Konno R, Dobbelaere KO, Godeaux OO, Tamura S, Yoshikawa H. Immunogenicity, reactogenicity, and safety of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women: interim analysis of a Phase II, double-blind, randomized controlled trial at month 7. Int. J. Gynecol. Cancer 19(5), 905-911 (2009).
83. Kim YJ, Kim KT, Kim JH et al. Vaccination with a human papillomavirus (HPV)-16/18 AS04-adjuvanted cervical cancer vaccine in Korean girls aged 10-14 years. J. Korean Med. Sci. 25(8), 1197-1204 (2010).
84. Ngan HY, Cheung AN, Tam KF et al. Human papillomavirus-16/18 AS04- adjuvanted cervical cancer vaccine: immunogenicity and safety in healthy Chinese women from Hong Kong. Hong Kong Med. J. 16(3), 171-179 (2010).
85. David MP, Van Herck K, Hardt K et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol. Oncol. 115(Suppl. 3), S1-S6 (2009).
86. Petäjä T, Keränen H, Karppa T et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04- adjuvanted vaccine in healthy boys aged 10-18 years. J. Adolesc. Health 44(1), 33-40 (2009).
87. Rivera Medina DM, Valencia A, de Velasquez A et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J. Adolesc. Health 46(5), 414-421 (2010).
88. Schwarz TF. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. Adv. Ther. 26(11), 983-998 (2009).
89. Garcia-Sicilia J, Schwarz TF, Carmona A et al. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted cervical cancer vaccine coadministered with combined diphtheria-tetanus- acellular pertussis-inactivated poliovirus vaccine to girls and young women. J. Adolesc. Health 46(2), 142-151 (2010).
90. Beran J. Safety and immunogenicity of a new hepatitis B vaccine for the protection of patients with renal insufficiency including pre-haemodialysis and haemodialysis patients. Expert Opin. Biol. Ther. 8(2), 235-247 (2008). (Pubitemid 351233716)
91. Kong NC, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. Kidney Int. 68(5), 2298-2303 (2005). (Pubitemid 43117807)
92. Kong NC, Beran J, Kee SA et al. A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients. Kidney Int. 73(7), 856-862 (2008). (Pubitemid 351398279)
93. Dasgupta G, Chentoufi AA, Nesburn AB, Wechsler SL, BenMohamed L. New concepts in herpes simplex virus vaccine development: notes from the battlefield. Expert Rev. Vaccines 8(8), 1023-1035 (2009).
94. Smith JS, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review. J. Infect. Dis. 186(Suppl. 1), S3-S28 (2002). (Pubitemid 35178845)
95. Cunningham AL, Diefenbach RJ, Miranda-Saksena M et al. The cycle of human herpes simplex virus infection: virus transport and immune control. J. Infect. Dis. 194(Suppl. 1), S11-S18 (2006). (Pubitemid 44420867)
96. Corey L, Wald A. Maternal and neonatal herpes simplex virus infections. N. Engl. J. Med. 361(14), 1376-1385 (2009).
97. Looker KJ, Garnett GP, Schmid GP. An estimate of the global prevalence and incidence of herpes simplex virus type 2 infection. Bull. World Health Organ. 86(10), 805-812 (2008).
98. Bourne N, Bravo FJ, Francotte M et al. Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J. Infect. Dis. 187(4), 542-549 (2003). (Pubitemid 36250017)
99. Stanberry LR, Spruance SL, Cunningham AL et al. Glycoprotein-D-adjuvant vaccine to prevent genital herpes. N. Engl. J. Med. 347(21), 1652-1661 (2002). (Pubitemid 35340783)
100. Descamps D, Hardt K, Spiessens B et al. Safety of human papillomavirus (HPV)- 16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum. Vaccin. 5(5), 1-9 (2009).
101. Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet 369(9580), 2161-2170 (2007). (Pubitemid 46977438)
102. Verstraeten T, Descamps D, David MP et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 26(51), 6630-6638 (2008).
103. Greenwood BM, Fidock DA, Kyle DE et al. Malaria: progress, perils, and prospects for eradication. J. Clin. Invest. 118(4), 1266-1276 (2008). (Pubitemid 351500419)
104. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A. From the circumsporozoite protein to the RTS,S/AS candidate vaccine. Hum. Vaccin. 6(1), 90-96 (2010).
105. Singh AP, Buscaglia CA, Wang Q et al. Plasmodium circumsporozoite protein promotes the development of the liver stages of the parasite. Cell 131(3), 492-504 (2007). (Pubitemid 350007696)
106. Garcia JE, Puentes A, Patarroyo ME. Developmental biology of sporozoite-host interactions in Plasmodium falciparum malaria: implications for vaccine design. Clin. Microbiol. Rev. 19(4), 686-707 (2006). (Pubitemid 44582977)
107. Egan JE, Weber JL, Ballou WR et al. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science 236(4800), 453-456 (1987). (Pubitemid 17071994)
108. Potocnjak P, Yoshida N, Nussenzweig RS, Nussenzweig V. Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J. Exp. Med. 151(6), 1504-1513 (1980). (Pubitemid 10062946)
109. Frevert U, Nardin E. Cellular effector mechanisms against Plasmodium liver stages. Cell. Microbiol. 10(10), 1956-1967 (2008).
110. Bojang KA, Milligan PJ, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358(9297), 1927-1934 (2001). (Pubitemid 34072872)
111. Alonso PL, Sacarlal J, Aponte JJ et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 364(9443), 1411-1420 (2004). (Pubitemid 39370716)
112. Alonso PL, Sacarlal J, Aponte JJ et al. Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet 366(9502), 2012-2018 (2005). (Pubitemid 41773376)
113. Vekemans J, Ballou WR. Plasmodium falciparum malaria vaccines in development. Expert Rev. Vaccines 7(2), 223-240 (2008). (Pubitemid 351357957)
114. Vekemans J, Leach A, Cohen J. Development of the RTS,S/AS malaria candidate vaccine. Vaccine 27(Suppl. 6), G67-G71 (2009).
115. Sacarlal J, Aide P, Aponte JJ et al. Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. J. Infect. Dis. 200(3), 329-336 (2009).
116. Aponte JJ, Aide P, Renom M et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled Phase I/IIb trial. Lancet 370(9598), 1543-1551 (2007). (Pubitemid 350018877)
117. Barbosa A, Naniche D, Aponte JJ et al. Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique. Infect. Immun. 77(10), 4502-4509 (2009).
118. Abdulla S, Oberholzer R, Juma O et al. Safety and immunogenicity of RTS,S/ AS02D malaria vaccine in infants. N. Engl. J. Med. 359(24), 2533-2544 (2008).
119. Bejon P, Lusingu J, Olotu A et al. Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 359(24), 2521-2532 (2008).
120. Kester KE, Cummings JF, Ofori-Anyinam O et al. Randomized, double-blind, Phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200(3), 337-346 (2009).
121. Polhemus ME, Remich SA, Ogutu BR et al. Evaluation of RTS,S/AS02A and RTS,S/AS01B in adults in a high malaria transmission area. PLoS ONE 4(7), e6465 (2009).
122. Waitumbi JN, Anyona SB, Hunja CW et al. Impact of RTS,S/AS02A and RTS,S/ AS01B on genotypes of P. falciparum in adults participating in a malaria vaccine clinical trial. PLoS ONE 4(11), e7849 (2009).
123. Stewart VA, McGrath SM, Walsh DS et al. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. Vaccine 24(42-43), 6483-6492 (2006). (Pubitemid 44511857)
124. Stewart VA, McGrath SM, Dubois PM et al. Priming with an adenovirus 35-circumsporozoite protein (CS) vaccine followed by RTS,S/AS01B boosting significantly improves immunogenicity to Plasmodium falciparum CS compared to that with either malaria vaccine alone. Infect. Immun. 75(5), 2283-2290 (2007). (Pubitemid 46744316)
125. Owusu-Agyei S, Ansong D, Asante K et al. Randomized controlled trial of RTS,S/ AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE 4(10), e7302 (2009).
126. Lell B, Agnandji S, von Glasenapp I et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS ONE 4(10), e7611 (2009).
127. Guinovart C, Aponte JJ, Sacarlal J et al. Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a Phase IIb trial in Mozambican children. PLoS ONE 4(4), e5165 (2009).
128. Audran R, Lurati-Ruiz F, Genton B et al. The synthetic Plasmodium falciparum circumsporozoite peptide PfCS102 as a malaria vaccine candidate: a randomized controlled Phase I trial. PLoS ONE 4(10), e7304 (2009).
129. Polhemus ME, Magill AJ, Cummings JF et al. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 25(21), 4203-4212 (2007). (Pubitemid 46635946)
130. Spring MD, Cummings JF, Ockenhouse CF et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 4(4), e5254 (2009).
131. Thera MA, Doumbo OK, Coulibaly D et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a Phase 1 randomized controlled trial. PLoS ONE 3(1), e1465 (2008).
132. Thera MA, Doumbo OK, Coulibaly D et al. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a Phase 1 randomized controlled trial. PLoS ONE 5(2), e9041 (2010).
133. Roestenberg M, Remarque E, de Jonge E et al. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel™, Montanide ISA 720 or AS02. PLoS ONE 3(12), e3960 (2008).
134. Ogutu BR, Apollo OJ, McKinney D et al. Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLoS ONE 4(3), e4708 (2009).
135. Cummings JF, Spring MD, Schwenk RJ et al. Recombinant liver stage antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-g/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine 28(31), 5135-5144 (2010).
136. Hollingdale MR, Aikawa M, Atkinson CT et al. Non-CS pre-erythrocytic protective antigens. Immunol. Lett. 25(1-3), 71-76 (1990). (Pubitemid 20260848)
137. Narum DL, Thomas AW. Differential localization of full-length and processed forms of PF83/AMA-1 an apical membrane antigen of Plasmodium falciparum merozoites. Mol. Biochem. Parasitol. 67(1), 59-68 (1994). (Pubitemid 24287311)
138. Diggs CL, Ballou WR, Miller LH. The major merozoite surface protein as a malaria vaccine target. Parasitol. Today 9(8), 300-302 (1993). (Pubitemid 23217729)
139. Kurtis JD, Hollingdale MR, Luty AJ, Lanar DE, Krzych U, Duffy PE. Pre-erythrocytic immunity to Plasmodium falciparum: the case for an LSA-1 vaccine. Trends Parasitol. 17(5), 219-223 (2001). (Pubitemid 32422165)
140. Silvie O, Franetich JF, Charrin S et al. A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. J. Biol. Chem. 279(10), 9490-9496 (2004). (Pubitemid 38296016)
141. Nabel GJ. Mapping the future of HIV vaccines. Nat. Rev. Microbiol. 5(7), 482-484 (2007). (Pubitemid 46925375)
142. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. Immunity 33(4), 542-554 (2010).
143. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 464(7286), 224-231 (2010).
144. Wijesundara DK, Jackson RJ, Ramshaw IA, Ranasinghe C. Human immunodeficiency virus-1 vaccine design: where do we go now? Immunol. Cell. Biol. 1-8 (2010).
145. Montefiori DC, Mascola JR. Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need? Curr. Opin. HIV AIDS 4(5), 347-351 (2009).
146. Goepfert PA, Tomaras GD, Horton H et al. Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 25(3), 510-518 (2007). (Pubitemid 44856093)
147. + T cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three adjuvant systems. Vaccine 28(43), 7016-7024 (2010).
148. + T cell responses in seronegative volunteers. Clin. Infect. Dis. 52(4), 522-531 (2011).
149. Coplan PM, Gupta SB, Dubey SA et al. Cross-reactivity of anti-HIV-1 T cell immune responses among the major HIV-1 clades in HIV-1-positive individuals from 4 continents. J. Infect. Dis. 191(9), 1427-1434 (2005). (Pubitemid 40563353)
150. + T cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol. 81(24), 13904-13915 (2007). (Pubitemid 350247883)
151. Kannanganat S, Kapogiannis BG, Ibegbu C et al. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J. Virol. 81(21), 12071-12076 (2007). (Pubitemid 47623838)
152. + T cells. J. Exp. Med. 200(6), 701-712 (2004). (Pubitemid 39299457)
153. + cytotoxic T lymphocyte responses to lentiviruses and herpesviruses. Curr. Opin. Immunol. 13(4), 479-482 (2001). (Pubitemid 32728482)
154. + T cells. Blood 107(12), 4781-4789 (2006). (Pubitemid 43882629)
155. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189(6), 991-998 (1999). (Pubitemid 29149355)
156. Lambotte O, Ferrari G, Moog C et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23(8), 897-906 (2009).
157. Hessell AJ, Hangartner L, Hunter M et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449(7158), 101-104 (2007). (Pubitemid 47373775)
158. Andersen P. Tuberculosis vaccines - an update. Nat. Rev. Microbiol. 5(7), 484-487 (2007). (Pubitemid 46925376)
159. Dye C, Williams BG. The population dynamics and control of tuberculosis. Science 328(5980), 856-861 (2010).
160. Russell DG, Barry CE 3rd, Flynn JL. Tuberculosis: what we don't know can, and does, hurt us. Science 328(5980), 852-856 (2010).
161. Kaufmann SH, Hussey G, Lambert PH. New vaccines for tuberculosis. Lancet 375(9731), 2110-2119 (2010).
162. Reed SG, Coler RN, Dalemans W et al. Defined tuberculosis vaccine, Mtb72F/ AS02A, evidence of protection in cynomolgus monkeys. Proc. Natl Acad. Sci. USA 106(7), 2301-2306 (2009).
163. Kaufmann SH. Recent findings in immunology give tuberculosis vaccines a new boost. Trends Immunol. 26(12), 660-667 (2005). (Pubitemid 41628199)
164. Von Eschen K, Morrison R, Braun M et al. The candidate tuberculosis vaccine Mtb72F/AS02A: tolerability and immunogenicity in humans. Hum. Vaccin. 5(7), 475-482 (2009).
165. Skeiky YA, Lodes MJ, Guderian JA et al. Cloning, expression, and immunological evaluation of two putative secreted serine protease antigens of Mycobacterium tuberculosis. Infect. Immun. 67(8), 3998-4007 (1999). (Pubitemid 29357020)
166. Al-Attiyah R, Mustafa AS, Abal AT, El-Shamy AS, Dalemans W, Skeiky YA. In vitro cellular immune responses to complex and newly defined recombinant antigens of Mycobacterium tuberculosis. Clin. Exp. Immunol. 138(1), 139-144 (2004). (Pubitemid 39279976)
167. Montoya J, Solon JA, Acosta L et al. An antigen and adjuvant system dose ranging safety and immunogenicity study of the M72 candidate tuberculosis vaccines in healthy Filipino adults. Trop. Med. Int. Health 14(Suppl. 2), 42 (2009) (Abstract).
168. Surquin M, Tielemans CL, Kulcsar I et al. Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02V-adjuvanted hepatitis B vaccine. Kidney Int 77(3), 247-255 (2010).
169. Vandepapelière P, Lau GK, Leroux-Roels G et al. Therapeutic vaccination of chronic hepatitis B patients with virus suppression by antiviral therapy: a randomized, controlled study of co-administration of HBsAg/AS02 candidate vaccine and lamivudine. Vaccine 25(51), 8585-8597 (2007). (Pubitemid 350192039)
170. Vandepapelière P, Horsmans Y, Moris P et al. Vaccine adjuvant systems containing monophosphoryl lipid A and QS-21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 26(10), 1375-1386 (2008).
171. Beran J, Hobzova L, Wertzova V et al. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum. Vaccin. 6(7), 578-584 (2010).
172. Gérard C, Debruyne C. Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer. Mol. Oncol. 3(5-6), 409-424 (2009).
173. Brichard VG, Lejeune D. Cancer immunotherapy targeting tumour-specific antigens: towards a new therapy for minimal residual disease. Expert Opin. Biol. Ther. 8(7), 951-968 (2008). (Pubitemid 352007006)
174. Vantomme V, Dantinne C, Amrani N et al. Immunologic analysis of a Phase I/II study of vaccination with MAGE-3 protein combined with the AS02B adjuvant in patients with MAGE-3-positive tumors. J. Immunother. 27(2), 124-135 (2004). (Pubitemid 38282732)
175. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12, 337-365 (1994). (Pubitemid 24140418)
176. Szmania S, Gnjatic S, Tricot G et al. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J. Immunother. 30(8), 847-854 (2007). (Pubitemid 350295364)
177. + T cell responses to MAGE-3 protein in lung cancer patients. J. Immunol. 172(5), 3289-3296 (2004). (Pubitemid 38263721)
178. Atanackovic D, Altorki NK, Cao Y et al. Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc. Natl Acad. Sci. USA 105(5), 1650-1655 (2008). (Pubitemid 351346569)
179. Vansteenkiste J, Zielinski M, Linder A et al. Final results of a multi-center, double-blind, randomized, placebo-controlled Phase II study adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC).J. Clin. Oncol. 25, 7554 (2007) (Abstract).
180. Kruit WH, Suciu S, Dreno B et al. Immunization with recombinant MAGE-A3 protein combined with adjuvant systems AS15 or AS02B in patients with unresectable and progressive metastatic cutaneous melanoma: a randomized open-label Phase II study of the EORTC Melanoma Group. J. Clin. Oncol. 26(15 Suppl.), 9065 (2008).
181. Klenerman P, Hill A. T cells and viral persistence: lessons from diverse infections. Nat. Immunol. 6(9), 873-879 (2005). (Pubitemid 43090441)
182. Koopman G, Mortier D, Hofman S et al. Immune-response profiles induced by human immunodeficiency virus type 1 vaccine DNA, protein or mixed-modality immunization: increased protection from pathogenic simian-human immunodeficiency virus viraemia with protein/DNA combination. J. Gen. Virol. 89(Pt 2), 540-553 (2008). (Pubitemid 351622452)
183. Sacarlal J, Aponte JJ, Aide P et al. Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine 26(2), 174-184 (2008). (Pubitemid 50008836)
184. Kester KE, Cummings JF, Ockenhouse CF et al. Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine 26(18), 2191-2202 (2008).